共 31 条
- [31] Comparable survival in newly diagnosed multiple myeloma (MM) after VAD induction with high dose therapy using melphalan 140mg/m2 + TBI 12 Gy (MEL+TBI) versus standard therapy with VBMCP and no benefit from interferon (IFN) maintenance:: Final clinical results of intergroup trial S9321 in the context of IFM 90 and MRC VII trials. BLOOD, 2004, 104 (11) : 156A - 157A